Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Front Psychiatry ; 12: 716488, 2021.
Article in English | MEDLINE | ID: covidwho-1430740

ABSTRACT

The COVID-19 pandemic is a collective trauma that is threatening citizens' mental health resulting in increased emotional stress, reduced social support, and heightened risk for affective symptoms. The present study aimed to investigate the effects of antenatal pandemic-related emotional stress and perceived social support on the symptoms of depression and anxiety of mothers who were pregnant during the initial COVID-19 outbreak in northern Italy. A sample of 281 mothers was enrolled at eight maternity units in the first hotspot region of the COVID-19 outbreak in northern Italy. Participants filled out online questionnaires assessing the direct or indirect exposure to the SARS-CoV-2 virus, pandemic-related stress, perceived social support, as well as symptoms of depression and anxiety. Depressive and anxious symptomatology was above clinical concern, respectively, in 26 and 32% of the respondents. Mothers who reported no exposure to SARS-CoV-2 during pregnancy and those who reported at least one direct or indirect exposure did not differ in terms of affective symptoms. Continuous scores and risk for severe depression and anxiety were positively associated with prenatal pandemic-related emotional stress and negatively linked with perceived social support during pregnancy. Women who become mothers during the COVID-19 emergency may be at high risk for affective problems. Dedicated preventive programs are needed to provide adequate preventive support and care for maternal mental health during and after the COVID-19 pandemic.

3.
Transfus Apher Sci ; 59(4): 102817, 2020 Aug.
Article in English | MEDLINE | ID: covidwho-1235989

ABSTRACT

Passive immunotherapy with plasma derived from patients convalescent from SARS-CoV-2 infection can be a promising approach in the treatment of COVID-19 patients. It is important that Blood Establishments are prepared to satisfy requests for immune plasma by defining the requirements applicable to plasma donors and the standards for preparation, qualification, storage, distribution and control of use of the product. This position paper is aimed to give recommendations on biological characteristics of a plasma preparation from convalescent donors and to support the evaluation of this therapeutic approach in more rigorous investigations.


Subject(s)
Betacoronavirus/immunology , Coronavirus Infections/therapy , Immunization, Passive , Pneumonia, Viral/therapy , Antibodies, Viral/blood , Blood Component Removal/methods , Blood Donors , COVID-19 , Coronavirus Infections/blood , Coronavirus Infections/immunology , Donor Selection/standards , Humans , Immune Sera/adverse effects , Immune Sera/isolation & purification , Immunization, Passive/adverse effects , Immunization, Passive/methods , Pandemics , Pneumonia, Viral/blood , Pneumonia, Viral/immunology , Product Labeling , Risk , SARS-CoV-2 , COVID-19 Serotherapy
4.
Transfus Med ; 31(3): 160-166, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-955504

ABSTRACT

OBJECTIVES: We evaluated how the Severe Acute Respiratory disease from Coronavirus 2 (SARS-CoV-2) epidemic impacted transfusion services, transfusion support required by Covid-19 patients and their clinical outcome. BACKGROUND: In Italy, the first confirmed case of SARS-CoV-2 infection was registered on 21 February 2020. As of 20 April, about 250 000 cases were registered, 1143 of which were in the province of Pescara. METHODS: We compared transfusion services provided by the blood centre of Pescara between 1 March and 20 April 2019 and between 1 March and 20 April 2020. We assessed the number and type of blood components donated, those transfused in the various hospital departments and those transfused to Covid-19 patients. RESULTS: Compared to 2019, we documented a decrease of 32% in the number of donations. The number of transfusions increased by 139% in the infectious diseases department (IDD), dedicated to Covid-19 patients, and by 76% in the intensive care unit (ICU), whereas it markedly decreased in the other departments. Of 299 patients with Covid-19, 60 were transfused (20.1%). Transfused patients in the ICU were significantly younger than those in IDD and had a lower number of lymphocytes, lower post-transfusion increment of haemoglobin levels and higher D-dimer and C reactive protein values. Mortality rate was 60.7% among transfused patients in the ICU and 39.0% among those in the IDD (p = 0.02). CONCLUSION: The Covid-19 epidemic had a profound impact on transfusion activities. The important blood demand for Covid-19 patients was satisfied because of the reduction in activities in other hospital wards. Covid-19-positive transfused patients showed a very poor prognosis.


Subject(s)
Blood Banks/statistics & numerical data , Blood Transfusion/statistics & numerical data , COVID-19/epidemiology , COVID-19/therapy , SARS-CoV-2 , Aged , Aged, 80 and over , Blood Component Transfusion/statistics & numerical data , Blood Donors/statistics & numerical data , Female , Hemoglobins/analysis , Humans , Intensive Care Units/statistics & numerical data , Italy/epidemiology , Male , Middle Aged , Pandemics , Treatment Outcome
5.
Blood Transfus ; 18(3): 163-166, 2020 05.
Article in English | MEDLINE | ID: covidwho-400777

ABSTRACT

Passive immunotherapy with plasma derived from convalescent patients recovering from SARS-CoV-2 infection can be a promising approach in the treatment of COVID-19 patients. It is important that blood establishments are ready to satisfy requests for immune plasma by defining the requirements applicable to plasma donors and the standards for preparation, qualification, storage, distribution, and control of product use. This Position paper aims to give recommendations on the biological characteristics of a plasma preparation from convalescent donors and to support the evaluation of this therapeutic approach in more rigorous investigations.


Subject(s)
Antibodies, Viral/therapeutic use , Betacoronavirus/immunology , Coronavirus Infections/therapy , Immunization, Passive/methods , Plasma/immunology , Pneumonia, Viral/therapy , Antibodies, Viral/adverse effects , Blood Banks/organization & administration , Blood Banks/standards , Blood Donors/legislation & jurisprudence , COVID-19 , Europe , Humans , Immunization Schedule , Immunization, Passive/adverse effects , Immunization, Passive/standards , Informed Consent , Italy , Pandemics , SARS-CoV-2 , COVID-19 Serotherapy
SELECTION OF CITATIONS
SEARCH DETAIL